维利帕尼联合卡铂和紫杉醇治疗BRCA突变晚期乳腺癌(BROCADE3):随机3期试验的最终总生存结果
BROCADE3研究在BRCA1/2突变、HER2阴性晚期乳腺癌患者中比较维利帕尼联合卡铂和紫杉醇与安慰剂联合卡铂和紫杉醇。最终总生存分析显示,两组中位总生存期分别为32.4个月和28.2个月(HR 0.916,95%CI 0.736-1.140,P=0.434),无进展生存期的改善未转化为总生存获益;两组均观察到较长生存时间,提示紫杉醇联合卡铂在该人群中有临床获益。
要点
- 最终OS:维利帕尼组32.4个月 vs 安慰剂组28.2个月(HR 0.916,P=0.434),无显著差异。
- 主要分析中PFS改善未转化为OS获益。
- 两组均观察到较长生存时间,提示紫杉醇联合卡铂有临床获益。
核心结论
- 最终OS数据表明,主要分析中显示的PFS改善未转化为OS获益。
- 两组均观察到较长生存时间,提示紫杉醇联合卡铂联合方案在BRCA1/2突变转移性乳腺癌人群中有临床获益。
研究设计与样本
- BROCADE3是一项随机3期研究,入组接受过≤2线转移性疾病化疗的BRCA1/2突变、HER2阴性晚期乳腺癌患者。
- 患者按2:1随机分配接受卡铂和紫杉醇联合维利帕尼或匹配安慰剂。
- OS为次要终点;意向治疗人群N=509,维利帕尼组337例,安慰剂组172例。
主要发现
- 意向治疗人群中,维利帕尼组中位OS为32.4个月,安慰剂组为28.2个月(HR 0.916;95%CI 0.736-1.140;P=0.434)。
- 维利帕尼更新安全性数据与主要分析报告一致,加用维利帕尼总体耐受良好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the BROCADE3 study, the addition of veliparib to carboplatin plus paclitaxel resulted in a significant improvement in progression-free survival (PFS) compared with placebo plus carboplatin and paclitaxel, in patients with germline BRCA1 or BRCA2 (BRCA1/2)-mutated, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We now report final overall survival (OS) data. METHODS: BROCADE3 is a randomized phase 3 study that enrolled patients with BRCA1/2-mutated, HER2-negative advanced breast cancer who received ≤ 2 prior lines of chemotherapy for metastatic disease. Patients were randomized 2:1 to carboplatin and paclitaxel, dosed with either veliparib or matching placebo. OS was a secondary endpoint. RESULTS: In the intention-to-treat population (N = 509), 337 patients were randomized to receive veliparib and 172 to placebo. Median OS was 32.4 months vs 28.2 months (hazard ratio, 0.916; 95% CI, 0.736-1.140; P = .434). The updated safety data for veliparib are consistent with those reported in the primary analysis; the addition of veliparib was generally well tolerated. CONCLUSIONS: Final OS data indicate that the PFS improvement shown in the primary analysis did not translate into an OS benefit. The long survival times observed in both arms suggest that combination therapy with paclitaxel and carboplatin provides clinical benefit in the population of patients with BRCA1/2-mutated metastatic breast cancer.
引用
- Diéras V, Han HS, Wildiers H, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024. PMID: 38309017. doi:10.1016/j.ejca.2024.113580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。